In accordance with 35 U.S.C. § 287(a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.
PRODUCT
PATENT INFORMATION
RYBELSUS® (semaglutide) tablets, for oral use
8,129,343
8,536,122
9,278,123
10,086,047
10,278,923
ESPEROCT® [Antihemophilic Factor (recombinant), GlycoPEGylated-exei]
7,199,223 8,133,977 8,143,378 8,247,536 8,536,126 9,150,848
FIASP® (insulin aspart recombinant)
8,324,157
6,899,699
RE46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
GLUCAGEN® (glucagon [rDNA origin])
No unexpired patents
LEVEMIR® (insulin detemir [rDNA origin] injection)
6,899,699
RE46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
NORDITROPIN® (somatropin [rDNA origin] injection)
6,899,699
RE 46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,861,757
D729,930
D765,833
9,775,953
10,220,155
10,357,616
10,376,652
NOVOEIGHT® (Antihemophilic Factor [Recombinant])
6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
8,399,620
9,982,033
NOVOLIN® 70/30 (70% NPH, human insulin isophane
suspension
[rDNA origin] and 30% human insulin, regular [rDNA
origin])
No unexpired patents
NOVOLIN® N (insulin suspension isophane [rDNA
origin])
No unexpired patents
NOVOLIN® R (insulin human [rDNA origin])
No unexpired patents
NOVOLOG® (insulin aspart [rDNA origin] injection)
For FLEXPEN and PENFILL presentations see respective entries
below
No unexpired patents
NOVOLOG® MIX 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin])
For FLEXPEN presentation see entry below
No unexpired patents
NOVOSEVEN® RT (Coagulation Factor VIIa [Recombinant])
8,299,029
8,658,597
8,729,022
OZEMPIC® (semaglutide)
6,899,699
7,762,994
8,114,833
8,129,343
8,536,122
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE46,363
9,616,180
9,861,757
D724,721
D758,571
10,220,155
US 10,335,462
10,357,616
10,376,652
PRANDIMET® (repaglinide/metformin HCI)
No unexpired patents
PRANDIN® (repaglinide)
No unexpired patents
REBINYN® (Coagulation Factor IX (recombinant), glycoPEGylated)
7,138,371
7,416,858
7,473,680
8,404,809
8,632,770
8,791,070
RYZODEG®70/30 (insulin degludec and insulin aspart injection)
7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
SAXENDA® (liraglutide [rDNA origin] injection)
6,268,343
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
9,968,659
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
TRESIBA® (insulin degludec injection)
7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant])
10,391,062
VAGIFEM® (estradiol vaginal tablets)
7,018,992
VICTOZA® (liraglutide [rDNA origin] injection)
6,268,343
8,114,833
8,846,618
9,968,659
RE41,956
7,762,994
8,579,869
9,265,893
XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection)
6,268,343
6,899,699
7,615,532
RE46,363
8,672,898
8,684,969
8,846,618
8,920,383
8,937,042
9,108,002
9,132,239
9,457,154
9,486,588
7,762,994
8,579,869
9,687,611
9,775,953
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
SOGROYA® (somapacitan-beco) injection
8,779,109
9,695,226
AUTOCOVER®
6,855,129
7,553,293
8,075,522
8,728,027
FLEXPEN®
RE 41,956
9,265,893
7,762,994
8,579,869
FLEXPRO®
6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D729,930
D765,833
7,762,994
8,579,869
9,775,953
9,616,180
9,861,757
10,220,155
10,357,616
10,376,652
FLEXPRO® PENMATE®
No unexpired patents
FLEXTOUCH®
6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D724,721
D734,450
D758,571
7,762,994
8,579,869
9,775,953
9,616,180
9,861,757
10,220,155
10,357,616
10,376,652
NOVOFINE® 32G
No unexpired patents
NOVOFINE® PLUS 32G
No unexpired patents
NOVOPEN® ECHO®
6,663,602
7,241,278
10,245,383
NOVOTWIST®
7,654,986
8,137,325
8,579,869
D675,316
7,762,994
PENFILL®
No unexpired patents
PENFILL® Cartridge
7,762,994
8,579,869
© 2015 Novo Nordisk All rights reserved. 0715-00027690-1 September 2015